AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Maleylacetoacetate isomerase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O43708

UPID:

MAAI_HUMAN

Alternative names:

GSTZ1-1; Glutathione S-transferase zeta 1

Alternative UPACC:

O43708; A6NED0; A6NNB8; A8MWD7; B2RCK3; O15308; O75430; Q6IB17; Q7Z610; Q9BV63

Background:

Maleylacetoacetate isomerase, also known by its alternative names GSTZ1-1 and Glutathione S-transferase zeta 1, plays a crucial role in metabolism. This bifunctional enzyme exhibits minimal glutathione-conjugating activity with various substrates and possesses maleylacetoacetate isomerase activity. It also demonstrates low glutathione peroxidase activity, contributing to cellular antioxidant defenses by catalyzing the glutathione-dependent oxygenation of specific compounds.

Therapeutic significance:

The enzyme is linked to Maleylacetoacetate isomerase deficiency, a benign metabolic disorder characterized by mild elevations in succinylacetone. Understanding the role of Maleylacetoacetate isomerase could open doors to potential therapeutic strategies, offering insights into metabolic disorders and the development of targeted treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.